Mayo Clinic Proceedings: Innovations, Quality & Outcomes (Dec 2020)

Hypoparathyroidism: An Uncommon Complication Associated With Immune Checkpoint Inhibitor Therapy

  • Omar M. El Kawkgi, MB, BCh, BAO,
  • Dingfeng Li, MD, MSc,
  • Anupam Kotwal, MBBS,
  • Robert A. Wermers, MD

Journal volume & issue
Vol. 4, no. 6
pp. 821 – 825

Abstract

Read online

As immune checkpoint inhibitor drugs are being used in the treatment of some cancers, unusual adverse events are being reported, labeled as immune-related adverse events. Various endocrinopathies related to immune-related adverse events have been described, among which hypoparathyroidism is exceedingly rare. We report a case of hypoparathyroidism induced by immune checkpoint drugs, highlighting the need for awareness of this emerging complication.